MX2019005127A - Poblaciones y productos de células madre mesenquimales y sus usos. - Google Patents

Poblaciones y productos de células madre mesenquimales y sus usos.

Info

Publication number
MX2019005127A
MX2019005127A MX2019005127A MX2019005127A MX2019005127A MX 2019005127 A MX2019005127 A MX 2019005127A MX 2019005127 A MX2019005127 A MX 2019005127A MX 2019005127 A MX2019005127 A MX 2019005127A MX 2019005127 A MX2019005127 A MX 2019005127A
Authority
MX
Mexico
Prior art keywords
products
stem cells
mesenchymal stem
cells populations
msc
Prior art date
Application number
MX2019005127A
Other languages
English (en)
Inventor
Brodie Chaya
BRODIE Shlomit
Original Assignee
Exostem Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exostem Biotec Ltd filed Critical Exostem Biotec Ltd
Publication of MX2019005127A publication Critical patent/MX2019005127A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invencion proporciona composiciones farmaceuticas que comprenden una poblacion de celulas estromales mesenquimales (CMM), vesiculas extracelulares secretadas de dicha poblacion de CMM y una combinacion de las mismas, y metodos de uso de las mismas en el tratamiento de una enfermedad o trastorno.
MX2019005127A 2016-11-03 2017-11-02 Poblaciones y productos de células madre mesenquimales y sus usos. MX2019005127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416821P 2016-11-03 2016-11-03
PCT/IL2017/051203 WO2018083700A1 (en) 2016-11-03 2017-11-02 Mesenchymal stem cells populations, their products, and use thereof

Publications (1)

Publication Number Publication Date
MX2019005127A true MX2019005127A (es) 2019-09-26

Family

ID=62075560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005127A MX2019005127A (es) 2016-11-03 2017-11-02 Poblaciones y productos de células madre mesenquimales y sus usos.

Country Status (10)

Country Link
US (1) US20190269739A1 (es)
EP (1) EP3534921A4 (es)
JP (1) JP2019535691A (es)
KR (1) KR20190109389A (es)
CN (1) CN110402146A (es)
AU (1) AU2017354272A1 (es)
CA (1) CA3042360A1 (es)
MX (1) MX2019005127A (es)
SG (1) SG11201903928WA (es)
WO (1) WO2018083700A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035101A1 (en) 2011-09-11 2013-03-14 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
JPWO2018159432A1 (ja) * 2017-03-03 2019-12-26 ロート製薬株式会社 間葉系幹細胞及び医薬組成物
EP3624817A4 (en) * 2017-05-16 2021-05-19 Exostem Biotec Ltd. METHODS OF INHIBITING AGING AND TREATING AGING-RELATED DISORDERS
CN112236131A (zh) 2018-03-29 2021-01-15 技术研究及发展基金有限公司 包含pten抑制剂的囊泡及其用途
CN108728408B (zh) * 2018-05-28 2021-08-24 天津博雅秀岩生物技术有限公司 犬胎膜间充质干细胞及制备方法和使用的培养基
WO2019235853A1 (ko) * 2018-06-05 2019-12-12 메디포스트(주) 히알루론산과 줄기세포를 포함하는 연골손상 관련 질환 치료용 약학 조성물
WO2020016900A1 (en) * 2018-07-18 2020-01-23 Exostem Biotec Ltd. Msc- and exosome-based immunotherapy
EP3823640A4 (en) * 2018-07-22 2022-05-18 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF MUSCULAR DISEASES
WO2020024071A1 (es) 2018-08-03 2020-02-06 Universidad Del Desarrollo Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
US20210395685A1 (en) * 2018-10-23 2021-12-23 The Johns Hopkins University Partioning of adult mesenchymal stem cells
AU2019374153A1 (en) * 2018-11-04 2021-06-10 Figene, Llc Treatment of cachexia using fibroblast cells and products thereof
CA3130744A1 (en) * 2019-02-19 2020-08-27 Direct Biologics Llc Acellular intravenous infusion including mesenchymal stem cell growth factors and exosomes
WO2020184729A1 (ja) * 2019-03-14 2020-09-17 北海道公立大学法人札幌医科大学 筋萎縮性側索硬化症の治療用医薬組成物
JP2022527507A (ja) * 2019-03-28 2022-06-02 エイジェックス・セラピューティクス・インコーポレイテッド 細胞外小胞を用いる組織再生の誘導
WO2020210458A1 (en) * 2019-04-12 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Pulsed focused ultrasound therapy for treatment of pancreatic disorders
ES2951396T3 (es) * 2019-10-18 2023-10-20 Amniotics Ab Procedimientos y aparatos para la obtención de células madre mesenquimales amnióticas a partir de líquido amniótico y sus células derivadas
KR102320436B1 (ko) * 2020-01-13 2021-11-03 주식회사 메타큐라 교모종줄기세포 엑소좀 유래 펩타이드를 포함하는 교모세포종의 진단용 바이오마커 조성물
CA3175322A1 (en) * 2020-03-17 2021-09-23 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
WO2021257533A2 (en) * 2020-06-15 2021-12-23 The Regents Of The University Of Michigan Microparticles for controlled release of extracellular vesicles and methods for fabricating the same
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
CN111973632B (zh) * 2020-08-25 2024-06-25 山东佰鸿干细胞生物技术有限公司 一种用于治疗糖尿病的干细胞制剂及其制备方法
WO2022074523A1 (en) * 2020-10-06 2022-04-14 Osiris Therapeutics, Inc. Primed placental tissue and uses in regenerative medicine
EP4245308A1 (en) * 2020-11-16 2023-09-20 Human Life Cord Japan Inc. Cell preparation to be used for preventing decrease in muscle mass
EP4005577A1 (en) 2020-11-26 2022-06-01 Novadip Biosciences Cellular and/or extracellular extracts for preventing and/or treating cancer and/or inflammation
KR102285160B1 (ko) * 2020-12-24 2021-08-03 주식회사 타임바이오 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물
KR102348920B1 (ko) * 2021-01-22 2022-01-11 메디포스트(주) Ptx-3, timp1 및 bdnf를 발현하는 간엽줄기세포를 유효성분으로 포함하는 염증 질환 또는 통증의 예방 또는 치료용 약학 조성물
CN113648417A (zh) * 2021-03-15 2021-11-16 中国人民解放军军事科学院军事医学研究院 Postn作为调控间充质干细胞分化能力的标志物及其应用
WO2022204955A1 (en) * 2021-03-30 2022-10-06 Shenzhen ChuangSheng XinKe Biotechnology Co., Ltd. Method for preparation of exosomes from ipscs and its derivatives for any clinical use thereof
KR102523933B1 (ko) * 2021-05-03 2023-04-20 고려대학교 산학협력단 융모막 추출물로부터 분리된 엑소좀을 유효성분으로 포함하는 골형성 촉진용 약학적 조성물
JP6974892B1 (ja) * 2021-05-27 2021-12-01 デクソンファーマシューティカルズ株式会社 癌悪液質の改善剤および癌悪液質の改善方法
WO2023007244A1 (en) * 2021-07-30 2023-02-02 Scarcell Therapeutics Mammalian cell population useful in cell therapy
CN113699115B (zh) * 2021-08-13 2023-09-22 中山大学附属第八医院（深圳福田） Dapk1在调控人骨髓来源msc的成脂分化能力中的用途
WO2023054317A1 (ja) * 2021-09-30 2023-04-06 国立大学法人東京大学 放射線による神経障害の処置に用いる細胞調製物
CN113897387B (zh) * 2021-10-09 2023-09-05 深圳市汉科生命工程有限公司 一种具有促进毛发再生功能的基因重组msc及其外泌体样纳米材料的制备方法和应用
CA3236885A1 (en) * 2021-11-01 2023-05-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating diseases associated with cellular-energy deficiency or mitochondrial dysfunction by locoregional delivery of extracellular vesicles that have a cargo with an enhanced bioenergetic profile
KR102438419B1 (ko) 2021-12-01 2022-09-01 메디포스트(주) Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물
WO2023114723A2 (en) * 2021-12-13 2023-06-22 Parker Institute For Cancer Immunotherapy Biomarkers for dendritic cells
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
WO2023183656A1 (en) * 2022-03-25 2023-09-28 Vitro Biopharma, Inc. Compositions, reagents, and methods for treating pitt-hopkins syndrome
CN114717185A (zh) * 2022-03-31 2022-07-08 秦岭大熊猫研究中心(陕西省珍稀野生动物救护基地) 一种大熊猫胎盘间充质干细胞分离与培养方法
CN115565608A (zh) * 2022-06-22 2023-01-03 中国食品药品检定研究院 一种鉴定样本中间充质干细胞的组织来源的方法及其用途
WO2024073722A2 (en) * 2022-09-30 2024-04-04 China Medical University Cell graft delivered in a delivery system and use thereof in regenerative medicine
WO2024102965A1 (en) * 2022-11-10 2024-05-16 Ohio State Innovation Foundation Designer extracellular vesicles for targeted delivery to muscle cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183579A1 (en) * 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
KR20120096793A (ko) * 2011-02-23 2012-08-31 (주)차바이오앤디오스텍 태반 유래 줄기세포를 포함한 면역반응억제용 조성물
DK2785359T3 (en) * 2011-11-30 2018-10-29 Astellas Inst For Regenerative Medicine MESENKYMAL STROMACELLES AND APPLICATIONS RELATED
ITTO20111183A1 (it) * 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
KR101555981B1 (ko) * 2013-05-01 2015-09-30 차의과학대학교 산학협력단 태반 유래 중간엽 줄기 세포, 또는 태반 유래 줄기세포로부터 유도된 신경 전구세포, 이를 포함하는 약학적 조성물, 질환 치료용 키트, 및 이를 이용하는 질환 치료방법
WO2015023901A1 (en) * 2013-08-15 2015-02-19 The Regents Of The University Of California Placenta-derived multipotent stem cells

Also Published As

Publication number Publication date
CN110402146A (zh) 2019-11-01
EP3534921A1 (en) 2019-09-11
CA3042360A1 (en) 2018-05-11
AU2017354272A1 (en) 2019-05-23
KR20190109389A (ko) 2019-09-25
JP2019535691A (ja) 2019-12-12
EP3534921A4 (en) 2020-06-03
US20190269739A1 (en) 2019-09-05
SG11201903928WA (en) 2019-05-30
WO2018083700A1 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2019005127A (es) Poblaciones y productos de células madre mesenquimales y sus usos.
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2020003351A (es) Metodos, composiciones y elementos implantables que comprenden celulas activas.
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
AU201612782S (en) Oral care implement
AU201612765S (en) Oral care implement
NZ737399A (en) Ccr2 modulators
AU201612818S (en) Oral care implement
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
AU201612579S (en) Oral care implement
MX2019002699A (es) Terapia genica para pacientes con anemia de fanconi.
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
MX2018000570A (es) Nuevas isoformas de tripsina y su uso.
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
PH12019500949A1 (en) Ror-gamma modulators
MX2018006226A (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
AU201612882S (en) Oral care implement